World's Best Scientists 2026 revealed!

D-Index & Metrics

Economics and Finance

D-Index
50
Citations
8987
World Ranking
1387
National Ranking
842

Overview

Louis P. Garrison is affiliated with the University of Washington in the United States. Their research spans multiple areas focused primarily on economics, health systems, and pharmaceutical policy. The main fields of study associated with their work include Economics, Econometrics and Finance as well as Medicine, with a significant contribution to Economics and Econometrics and General Health Professions as notable subfields.

The scientist has explored diverse topics, including:

  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy
  • Healthcare cost, quality, practices
  • Economic and Financial Impacts of Cancer
  • Biosimilars and Bioanalytical Methods
  • Hemophilia Treatment and Research
  • Innovation Policy and R&D

Frequent coauthors with whom they have collaborated include:

  • William B. Wong
  • Meng Li
  • David L. Veenstra
  • Boshen Jiao
  • Stacey Kowal

Louis P. Garrison's publications often appear in respected venues such as:

  • Value in Health
  • Journal of Managed Care & Specialty Pharmacy
  • PharmacoEconomics
  • Journal of Medical Economics
  • Journal of Clinical Oncology

Some of their recent papers include:

  • "Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations," 2020, published in Pain
  • "The History and Future of the 'ISPOR Value Flower': Addressing Limitations of Conventional Cost-Effectiveness Analysis," 2022, published in Value in Health
  • "HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies," 2020, published in The European Journal of Health Economics
  • "Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A," 2020, published in Journal of Medical Economics
  • "Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective," 2020, published in Journal for ImmunoTherapy of Cancer

Best Publications

  • Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

    Louis P. Garrison;Peter J. Neumann;Pennifer Erickson;Deborah Marshall

  • Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].

    Darius N. Lakdawalla;Jalpa A. Doshi;Louis P. Garrison;Charles E. Phelps

  • Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

    Josh J. Carlson;Sean D. Sullivan;Louis P. Garrison;Peter J. Neumann

  • Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

    Louis P. Garrison;Adrian Towse;Andrew Briggs;Gerard de Pouvourville

  • An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].

    Louis P. Garrison;Mark V. Pauly;Richard J. Willke;Peter J. Neumann

  • Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

    Eric Faulkner;Lieven Annemans;Lou Garrison;Mark Helfand

  • Good research practices for measuring drug costs in cost-effectiveness analyses

    Louis P. Garrison;Edward C. Mansley;Thomas A. Abbott;Brian W. Bresnahan

  • Economic Evaluation of Influenza Pandemic Mitigation Strategies in the United States Using a Stochastic Microsimulation Transmission Model

    Beate Sander;Azhar Nizam;Louis P. Garrison;Maarten J. Postma

  • A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]

    Louis P. Garrison;Peter J. Neumann;Richard J. Willke;Anirban Basu

  • Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

    Adrian Towse;Louis P. Garrison

  • Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

    Cassidy J;Douillard Jy;Twelves C;McKendrick Jj

  • Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer

    Louis P. Garrison;Deborah Lubeck;Deepa Lalla;Virginia Paton

  • A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1]

    Peter J. Neumann;Richard J. Willke;Louis P. Garrison

  • Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations.

    Shannon M Smith;Robert H Dworkin;Dennis C Turk;Michael McDermott

  • Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis

    Louis P. Garrison;Sachin Kamal-Bahl;Adrian Towse

  • Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

    Joel W. Hay;Jim Smeeding;Norman V. Carroll;Michael Drummond

  • Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report

    Josephine Mauskopf;Baudouin Standaert;Mark P. Connolly;Anthony J. Culyer

  • Interspecialty variation in office-based care.

    Greenwald Hp;Peterson Ml;Garrison Lp;Hart Lg

  • Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis

    Louis P. Garrison;Adrian Towse;Brian W. Bresnahan

  • A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.

    David L Veenstra;Joshua A Roth;Louis P Garrison;Scott D Ramsey;Scott D Ramsey

  • Global Eradication of Measles: An Epidemiologic and Economic Evaluation

    Ann Levin;Colleen Burgess;Louis P. Garrison;Chris Bauch

  • Linking pharmacogenetics-based diagnostics and drugs for personalized medicine.

    Louis P. Garrison;M.J. Finley Austin

Frequent Co-Authors

Adrian Towse
Adrian Towse Office Of Health Economics
James G. Kublin
James G. Kublin Fred Hutchinson Cancer Research Center
Anirban Basu
Anirban Basu University of Washington
Edith A. Perez
Edith A. Perez Mayo Clinic
Mark P. Jensen
Mark P. Jensen University of Washington
Christopher Eccleston
Christopher Eccleston University of Bath
Roy Freeman
Roy Freeman Beth Israel Deaconess Medical Center
Mondher Toumi
Mondher Toumi Aix-Marseille University
Mark Jit
Mark Jit New York University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Economics and Finance opens the door to many educational pathways tailored to evolving industry needs. For those seeking rapid advancement, 1 year mba programs in usa provide an intensive curriculum that prepares graduates for leadership roles in a short timeframe.

If your interests include building and managing new ventures, pursuing an online mba entrepreneurship degree can equip you with practical skills for launching startups or innovating within existing organizations. Affordability and flexibility are key benefits of this study mode.

Project management is another growing area in business. Understanding what is a project management degree can help you determine how these credentials lead to roles in planning, executing, and overseeing complex projects across various industries.

Finally, for those looking to balance budget and quality, the cheapest online finance degree options offer a fast and cost-effective way to gain credentials that are increasingly sought after in banking, investment, and corporate finance sectors.

Best Scientists Citing Louis P. Garrison

Trending Scientists

Recently Published Articles